Concizumab (commercial name, Alhemo), a monoclonal antibody was approved by the FDA on 20 December 2024 for prevention of bleeding episodes in patients with...
On 11 October 2024, Hympavzi (marstacimab-hncq), a human monoclonal antibody targeting “tissue factor pathway inhibitor” received US FDA’s approval as a new drug for...